• Explore /
  • Poster
  • / Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.

Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.

Abstract Poster

Authors

null

Aaron C. Tan

National Cancer Centre Singapore, Singapore, Singapore

Aaron C. Tan , Do-Youn Oh , Yee Chao , Chih-Yi Hsieh , Wei-Ling Chang , Fenny Isanto , Ying-Chen Chen , Mark McHale , Bertil Lindmark , Matthew C.H. Ng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02648425, NCT02435927, and NCT02992340

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 331)

DOI

10.1200/JCO.2019.37.4_suppl.331

Abstract #

331

Poster Bd #

H9

Abstract Disclosures

Similar Posters

First Author: Do-Youn Oh

First Author: Milind M. Javle

First Author: Choong-kun Lee

First Author: Choong-kun Lee